Terms: = Thyroid cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Prognosis
7 results:
1. IL-17 A correlates with disease progression in papillary thyroid carcinoma.
Banerjee S; Nahar U; Dahiya D; Gupta R; Mukherjee S; Sachdeva N; Sood A; Dey P; Radotra B; Bhansali A
Diagn Pathol; 2023 Aug; 18(1):93. PubMed ID: 37563607
[TBL] [Abstract] [Full Text] [Related]
2. PTPRC promoted CD8+ T cell mediated tumor immunity and drug sensitivity in breast cancer: based on pan-cancer analysis and artificial intelligence modeling of immunogenic cell death-based drug sensitivity stratification.
Li P; Wang W; Wang S; Cao G; Pan T; Huang Y; Wan H; Zhang W; Huang Y; Jin H; Wang Z
Front Immunol; 2023; 14():1145481. PubMed ID: 37388747
[TBL] [Abstract] [Full Text] [Related]
3. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis.
Han LT; Hu JQ; Ma B; Wen D; Zhang TT; Lu ZW; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
Diagn Pathol; 2019 Jun; 14(1):52. PubMed ID: 31159823
[TBL] [Abstract] [Full Text] [Related]
4. Effect of high-dose intravenous vitamin C on inflammation in cancer patients.
Mikirova N; Casciari J; Rogers A; Taylor P
J Transl Med; 2012 Sep; 10():189. PubMed ID: 22963460
[TBL] [Abstract] [Full Text] [Related]
5. Bexarotene and DAB(389)il-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract] [Full Text] [Related]
6. Innovative strategies for the treatment of thyroid cancer.
Schmutzler C; Koehrle J
Eur J Endocrinol; 2000 Jul; 143(1):15-24. PubMed ID: 10870026
[TBL] [Abstract] [Full Text] [Related]
7. Changes of cytokines and thyroid function in patients with recurrent breast cancer.
Yokoe T; Iino Y; Takei H; Horiguchi J; Koibuchi Y; Maemura M; Ohwada S; Morishita Y
Anticancer Res; 1997; 17(1B):695-9. PubMed ID: 9066604
[TBL] [Abstract] [Full Text] [Related]
